表紙
市場調査レポート

生殖技術:製品および世界市場

Human Reproductive Technologies: Products and Global Markets

発行 BCC Research 商品コード 290777
出版日 ページ情報 英文 175 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
生殖技術:製品および世界市場 Human Reproductive Technologies: Products and Global Markets
出版日: 2013年11月30日 ページ情報: 英文 175 Pages
概要

当レポートでは、世界における最新の生殖技術・製薬市場について包括的に調査し、市場規模、市場参入企業およびパイプライン製品・技術の特定、治療タイプ・適応症別の分析を提供しており、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 産業概要

  • 生殖器官の構造・機能
  • 女性・男性の生殖器官の神経ホルモン制御
  • リプロダクティブヘルスの課題・動向
  • 人口統計

第4章 不妊市場

  • 不妊のイントロダクション・概要

第5章 治療法

  • 不妊治療薬
  • イントロダクション・種類
  • 市場収益・予測
  • 不妊治薬の将来の進歩
  • 競合分析

第6章 生殖支援技術

  • イントロダクション
  • 米国の不妊治療クリニック
  • 世界の不妊治療クリニック
  • 市場収益・予測
  • 生殖支援技術の将来の動向
  • 競合分析

第7章 不妊診断

  • イントロダクション
  • 市場収益・予測
  • 競合分析
  • 診断不妊治療における将来の進歩
  • 不妊治療市場全体の収益・予測

第8章 避妊市場

  • 避妊のイントロダクション・概要
  • 医薬品
  • 避妊のその他の投薬計画
  • 市場収益・予測
  • 競合分析
  • 処方装置
  • 市場収益・予測
  • 競合分析
  • 避妊における将来の進歩
  • 市場全体の収益・予測

第9章 性機能障害市場

  • イントロダクション・概要
  • 市場収益・予測
  • 競合分析
  • デバイス
  • 市場収益・予測
  • メーカーの売り上げ水準推計
  • 競合分析
  • 性機能障害における将来の進歩
  • 総市場収益・予測

第10章 特許

  • 特許分析:メーカー別
  • 特許:アプリケーション別

第11章 市場の主要メーカー

第12章 総市場

  • 世界の生殖技術・製品市場全体:地域別
  • 総市場規模:分類別
  • 参入企業:分類別
  • 総市場規模:製品タイプ別

第13章 市場参入企業

  • 企業プロファイル

第14章 付録A

第15章 付録B

図表一覧

目次
Product Code: HLC017D

The objective of the study is to present a comprehensive, up-to-date look at the market for reproductive technologies and products. Markets are divided according to treatment type and indication. The products in some markets are mature, while products in other markets are just beginning to emerge. The report is directed to decision-makers in the various areas of reproductive drugs and technologies, and it provides insight into those arenas for current and future development.

REASONS FOR STUDY

This BCC Research study is presented to increase the awareness of the global reproductive market by identifying pharmaceutical preparations, devices, technologies and important advancements within the industry. The study analyzes the new therapeutics and technologies for reproductive health and it addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and technologies have stepped up discovery, as the engine driving growth in all markets is research and development.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies.

The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.

  • Infertility market-male and female factors, pharmaceuticals and future advancements.
    • IVF.
    • Assistive reproductive technologies.
    • Fertility diagnostics.
  • Contraception-pharmaceuticals and devices.
  • Sexual dysfunction-pharmaceuticals and devices.

Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013.

ANALYST CREDENTIALS

Mary Anne Crandall is a Medical Analyst, specializing in the pharmaceuticals industry for 20 years, currently working on a Ph.D. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR STUDY
  • SCOPE OF STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • INTENDED AUDIENCE
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • SUMMARY FIGURE: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ BILLIONS)

CHAPTER 3 - INDUSTRY OVERVIEW

  • STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM
    • MALE
    • FEMALE
      • Neuroendocrine Regulation
      • Menarche
      • Menstruation Cycle
    • PHASES OF SEXUAL RESPONSES
      • TABLE 1: STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
    • Male Sexual Response
    • Female Sexual Response
  • NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE SYSTEM
    • Estrogen
      • Progestogens
      • Testosterone
    • EFFECTS OF AGING
  • ISSUES AND TRENDS OF REPRODUCTIVE HEALTH
    • CONTRACEPTIVE INSURANCE
    • OVER-THE-COUNTER BIRTH CONTROL PILLS
    • PREIMPLANTATION GENETIC DIAGNOSIS
    • DESIGNER BABIES
    • NEW USE FOR CONTRACEPTIVES
    • AGING AND INFERTILITY
    • DEATH BY CONTRACEPTIVE PATCH
    • SEXUAL DYSFUNCTION AND CANCER
    • INFERTILITY AND CANCER
      • Chemotherapy
      • Radiation
      • Prevention Strategies
      • Procreative Alternatives
    • SIGNALING PATHWAY FOR FERTILITY TREATMENT
    • MARKETING TACTICS
    • MALE BIRTH CONTROL
    • MERCHANDISING TARGETING WOMEN
    • COUNTERFEIT PRODUCTS
    • SURPLUS EMBRYOS AND FETUSES
    • STEM CELL AND OTHER CONTROVERSIAL ISSUES - SELECTED INTERNATIONAL VIEWS
    • CONTROVERSIAL DISPOSAL OF EMBRYOS
  • DEMOGRAPHICS
    • UNITED STATES
      • TABLE 2: U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)
      • FIGURE 1: U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)
      • TABLE 3: U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2030 (THOUSANDS/%)
      • FIGURE 2: U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030 (%)
      • TABLE 4: CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND 2008 (PER 1,000 WOMEN)
      • TABLE 5: WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980-2008
      • TABLE 6: ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
    • EU
      • TABLE 7: BIRTH RATE BY EU COUNTRY AND YEAR, 1960-2011 (PER 1,000 POPULATION (%))
    • ASIA

CHAPTER 4 - INFERTILITY MARKET

  • INTRODUCTION AND OVERVIEW OF INFERTILITY
    • DEFINITION OF INFERTILITY
    • ETIOLOGY OF INFERTILITY
    • EVALUATION OF FERTILITY
      • Male Factor
      • Artificial Insemination
      • Vaginal and Cervical Factors
      • Immunological Factors
      • Uterine and Tubal Factors
      • Ovarian Factors
    • UNEXPLAINED INFERTILITY
    • MULTIPLE BIRTHS
    • ASIA FACTOR

CHAPTER 5 - METHODS OF TREATMENT

  • FERTILITY PHARMACEUTICALS
  • INTRODUCTION AND TYPES
    • Antagon
    • Bravelle
    • Cetrotide
    • Clomid
    • Crinone and Prometrium
    • Fertinex
    • Follistim
    • Gonal-F
    • Humegon
    • Lupron
    • Novarel
    • Ovidrel
    • Parlodel
    • Pregnyl
    • Profasi
    • Prometrium
    • Repronex
    • Serophene
      • TABLE 8: SELECTED PRESCRIPTION FERTILITY DRUGS
  • MARKET REVENUES AND FORECAST
    • TABLE 9: MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • FUTURE ADVANCEMENTS IN INFERTILITY PRODUCTS
    • CORIFOLLITROPIN ALFA INJECTION
    • PROGESTERONE VAGINAL RING
    • XM17
      • TABLE 10: INFERTILITY DRUGS IN DEVELOPMENT
  • COMPETITIVE ANALYSIS
    • TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 3: INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY REVENUES, 2013 (%)

CHAPTER 6 - ASSISTIVE REPRODUCTIVE TECHNOLOGIES

  • INTRODUCTION
    • TYPES
      • IVF
      • Ovulation Induction
      • Oocyte Retrieval
      • Intracytoplasmic Sperm Injection (ICSI)
      • Fertilization
      • Embryo Transfer
      • Results of IVF
    • GIFT
    • ZIFT
    • WOMBS FOR RENT
    • OOCYTE DONATION
    • FROZEN EMBRYOS
  • UNITED STATES FERTILITY CLINICS
    • TABLE 12: NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011 (U.S.)
    • TABLE 13: NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%)
    • TABLE 14: PREGNANCY SUCCESS RATES, 2011
  • INTERNATIONAL FERTILITY CLINICS
    • TABLE 15: NUMBER OF IVF CENTERS BY SELECT COUNTRIES
  • MARKET REVENUES AND FORECAST
    • TABLE 16: MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
  • FUTURE TRENDS IN ASSISTIVE REPRODUCTIVE TECHNOLOGY
  • COMPETITIVE ANALYSIS
    • TABLE 17: GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 4: GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY REVENUES, 2013 (%)

CHAPTER 7 - FERTILITY DIAGNOSTICS

  • INTRODUCTION
    • TYPES
      • Urine Studies
        • Pregnancy Testing
        • Ovulation Testing
        • Sperm Testing
      • Hormone Studies
      • Blood Studies
  • MARKET REVENUES AND FORECAST
    • TABLE 18: MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
  • COMPETITIVE ANALYSIS
    • TABLE 19: FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 5: FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
  • FUTURE ADVANCEMENTS IN DIAGNOSTIC FERTILITY TREATMENT
  • TOTAL INFERTILITY MARKET REVENUES AND FORECAST
    • TABLE 20: MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 6: MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)

CHAPTER 8 - CONTRACEPTION MARKET

  • INTRODUCTION AND OVERVIEW OF CONTRACEPTION
    • TABLE 21: CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44., 2011 (THOUSANDS)
    • TABLE 22: CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT)
  • PHARMACEUTICALS
    • Types
    • Oral Contraceptives
      • TABLE 23: MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES, 2013
    • Alesse
    • Beyaz
    • Brevicon and Norinyl
    • Desogen
    • Estrostep
    • Levlen ED
    • Levora
    • Lo -Loestrin
    • Lo/Ovral
    • Low-Ogestrel
    • Lybrel
    • Microgestin
    • Mircette
    • Natazia
    • Necon
    • Nordette
    • Nor-QD
    • Ortho Evra
    • Ortho Micronor
    • Ortho Tri-Cyclen
    • OrthoCept
    • Ovcon 35
    • Ovral
    • Quartette
    • Safyral
    • Seasonale
    • Tri-Levlen
    • Tri-Norinyl
    • Triphasil
    • Trivora
    • Yasmin 28
    • Zovia
    • Zoely
      • TABLE 24: ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
      • TABLE 25: POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
      • TABLE 26: CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
  • OTHER DRUG REGIMENS FOR CONTRACEPTION
    • Depo-Provera
    • Plan B One Step
      • Mifeprex
  • MARKET REVENUES AND FORECAST
    • TABLE 27: MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • COMPETITIVE ANALYSIS
    • TABLE 28: GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 7: GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
  • PRESCRIPTION DEVICES
    • INTRODUCTION AND TYPES
      • Intrauterine Devices
        • NuvaRing
        • Implanon
    • TABLE 29: SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013
  • MARKET REVENUES AND FORECAST
    • TABLE 30: MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • COMPETITIVE ANALYSIS
    • TABLE 31: GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 8: CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
  • FUTURE ADVANCEMENTS IN CONTRACEPTION
    • TABLE 32: CONTRACEPTIVES IN DEVELOPMENT
    • AG-200-15
    • ARC
    • C31G (SAVVY)
    • FC PATCH
    • LECETTE
    • AG890
    • USHERCELL
    • LEVOSERT IUD
  • TOTAL MARKET REVENUES AND FORECAST
    • TABLE 33: MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 9: MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)

CHAPTER 9 - SEXUAL DYSFUNCTION MARKET

  • INTRODUCTION AND OVERVIEW
    • TYPES OF SEXUAL DYSFUNCTION
    • CAUSES OF SEXUAL DYSFUNCTION
    • DEMOGRAPHICS OF SEXUAL DYSFUNCTION
    • PHARMACEUTICALS
      • Introduction and Types
        • Viagra
        • Cialis
        • Levitra
        • Staxyn
        • Stendra/Spendra
        • Yohimbine
        • Caverject
        • MUSE
          • TABLE 34: SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS
  • MARKET REVENUES AND FORECAST
    • TABLE 35: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • COMPETITIVE ANALYSIS
    • TABLE 36: GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 10: GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
  • DEVICES
    • Introduction and Types
      • SomaTherapy-ED SOMAerect Stf
      • Viberect
      • Erectaid Classic System
      • AMS Inflatable Penile Implant
      • Coloplast Titan OTR
    • TABLE 37: SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS
  • MARKET REVENUES AND FORECAST
    • TABLE 38: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT
  • ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
  • COMPETITIVE ANALYSIS
    • TABLE 39: GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • FIGURE 11: GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
  • FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION
    • TABLE 40: SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
    • Flibanserin
    • Femprox
    • LibiGel
    • Lybrido and Lybridos
    • Tefina
    • Topiglan
    • Zoraxel
    • Zydena (udenafil)
  • TOTAL MARKET REVENUES AND FORECAST
    • TABLE 41: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 12: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)

CHAPTER 10 - PATENTS

  • PATENT ANALYSIS BY MANUFACTURER
    • TABLE 42: SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
  • PATENTS BY APPLICATION
    • INFERTILITY TREATMENTS
    • CONTRACEPTION
    • SEXUAL DYSFUNCTION

CHAPTER 11 - LEADING MARKET MANUFACTURERS

  • TABLE 43: PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT

CHAPTER 12 - TOTAL MARKET

  • TABLE 44: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
  • TOTAL GLOBAL MARKET FOR REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY REGION
    • TABLE 45: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%)
    • FIGURE 13: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%)
    • TABLE 46: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%)
    • FIGURE 14: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%)
  • TOTAL MARKET SIZE BY CATEGORY
    • TABLE 47: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 15: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
    • TABLE 48: TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2013 ($ MILLIONS/%)
    • FIGURE 16: NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013
    • FIGURE 17: MARKET SHARE BY MARKET SEGMENT, 2013 (%)
  • INDUSTRY PARTICIPANTS BY CATEGORY
    • TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
  • TOTAL MARKET SIZE BY PRODUCT TYPE
    • TABLE 50: TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 18: TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)

CHAPTER 13 - PARTICIPATING COMPANIES

  • COMPANY PROFILES
    • ACTAVIS, INC
    • BAYER AG
    • BRISTOL-MYERS SQUIBB CO.
    • CHURCH & DWIGHT COMPANY INC.
    • COOPERSURGICAL INC.
    • ELI LILLY & CO.
    • EMD SERONO, INC
    • FERRING PHARMACEUTICALS
    • GLAXOSMITHKLINE PLC
    • JANSSEN PHARMACEUTICAL
    • MERCK INC.
    • NOVARTIS INTERNATIONAL AG
    • PFIZER INC.
    • PRINCETON BIOMEDITECH CORP.
    • QUIDEL CORP
    • VIVUS INC.

CHAPTER 14 - APPENDIX A

  • SELECTED LIST OF U.S. FERTILITY CLINICS
    • ALABAMA
    • ARIZONA
    • CALIFORNIA
    • COLORADO
    • CONNECTICUT
    • DISTRICT OF COLUMBIA
    • FLORIDA
    • GEORGIA
    • IDAHO
    • ILLINOIS
    • INDIANA
    • KANSAS
    • MAINE
    • MARYLAND
    • MASSACHUSETTS
    • MICHIGAN
    • MINNESOTA
    • MONTANA
    • NEVADA
    • NEW HAMPSHIRE
    • NEW JERSEY
    • NEW YORK
    • NORTH CAROLINA
    • OREGON
    • RHODE ISLAND
    • SOUTH CAROLINA
    • SOUTH DAKOTA
    • TEXAS
    • UTAH
    • VIRGINIA
    • WASHINGTON
  • SELECTED LIST OF FERTILITY CLINICS IN OTHER REGIONS
    • ASIAN FERTILITY CLINICS
    • AUSTRIA
      • Innsbruck
      • Vienna
    • SWITZERLAND
      • Basel
      • Geneva
      • Zurich
    • GERMANY
    • FRANCE
      • Paris
    • ITALY
      • Naples
      • Rome
    • GREAT BRITAIN
      • London

CHAPTER 15 - APPENDIX B: LIST OF COMPANIES

  • TABLE 51: LIST OF COMPANIES

LIST OF TABLES

  • SUMMARY TABLE: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 1: STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
    • TABLE 2: U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)
    • TABLE 3: U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2030 (THOUSANDS/%)
    • TABLE 4: CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND 2008 (PER 1,000 WOMEN)
    • TABLE 5: WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980-2008
    • TABLE 6: ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
    • TABLE 7: BIRTH RATE BY EU COUNTRY AND YEAR, 1960-2011 (PER 1,000 POPULATION (%))
    • TABLE 8: SELECTED PRESCRIPTION FERTILITY DRUGS
    • TABLE 9: MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 10: INFERTILITY DRUGS IN DEVELOPMENT
    • TABLE 11: GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 12: NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011 (U.S.)
    • TABLE 13: NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%)
    • TABLE 14: PREGNANCY SUCCESS RATES, 2011
    • TABLE 15: NUMBER OF IVF CENTERS BY SELECT COUNTRIES
    • TABLE 16: MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 17: GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 18: MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 19: FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 20: MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 21: CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44., 2011 (THOUSANDS)
    • TABLE 22: CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT)
    • TABLE 23: MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES, 2013
    • TABLE 24: ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
    • TABLE 25: POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
    • TABLE 26: CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
    • TABLE 27: MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 28: GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 29: SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013
    • TABLE 30: MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 31: GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 32: CONTRACEPTIVES IN DEVELOPMENT
    • TABLE 33: MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS
    • TABLE 35: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 36: GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 37: SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS
    • TABLE 38: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%)
    • TABLE 40: SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
    • TABLE 41: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 42: SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
    • TABLE 43: PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
    • TABLE 44: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS)
    • TABLE 45: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%)
    • TABLE 46: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%)
    • TABLE 47: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2013 ($ MILLIONS/%)
    • TABLE 49: REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
    • TABLE 50: TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS)
    • TABLE 51: LIST OF COMPANIES

LIST OF FIGURES

  • SUMMARY FIGURE: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ BILLIONS)
    • FIGURE 1: U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS)
    • FIGURE 2: U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030 (%)
    • FIGURE 3: INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY REVENUES, 2013 (%)
    • FIGURE 4: GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY REVENUES, 2013 (%)
    • FIGURE 5: FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
    • FIGURE 6: MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
    • FIGURE 7: GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
    • FIGURE 8: CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
    • FIGURE 9: MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
    • FIGURE 10: GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
    • FIGURE 11: GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARES BY ESTIMATED REVENUES, 2013 (%)
    • FIGURE 12: MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
    • FIGURE 13: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%)
    • FIGURE 14: GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%)
    • FIGURE 15: TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
    • FIGURE 16: NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013
    • FIGURE 17: MARKET SHARE BY MARKET SEGMENT, 2013 (%)
    • FIGURE 18: TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS)
Back to Top